Faron Pharmaceuticals Ltd has appointed new leadership as the company prepares to advance clinical development of bexmarilimab, its wholly-owned immunotherapy for both haematological and solid tumours. The company’s founder and chief executive officer, Markku Jalkanen, is to retire and be replaced by his son, Juho Jalkanen, currently the chief operating officer. The new CEO will take up his position on 1 May.
